Travoprost patient responses revealed

Article

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

Dr J.M. Martinez-de-la-Casa et al., Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain, observed 64 patients who were scheduled for cataract surgery without any additional ophthalmologic pathology.

Two hours before surgery a single drop of travoprost 0.004% was administered in the eye due for operation. AL-5848 concentration was determined by extracting a sample of aqueous humour.

They were compared to three patient groups identified by CCT measurements obtained by ultrasound pachymetry. Group 1 had a CCT 574 microns.

The results demonstrated a mean AL-5848 concentration of 3.27±2.03 in group 1, 3.27±2.44 ng/mL in Group II and 2.73±2.15ng/mL in group 3, meaning there were no significant differences between the groups.

The paper, published in the journal Eye can be read here.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.